Highest-materiality recent filing
Taysha Q2 2026 net loss $46.6M; TSHA-102 pivotal dosing complete, $230M raised
Net loss $46.6M ($0.13/share) vs $26.9M ($0.09) in Q2 2025; R&D expenses $38.6M vs $20.1M.
Taysha Gene Therapies prices $200M public offering of 32.5M shares at $6.00/share
Offering of 32,500,001 shares at $6.00/share and 833,333 pre-funded warrants at $5.999.
Completed dosing of 17 patients in REVEAL pivotal trial; topline 6-month interim data and FDA feedback expected 1H 2027.
Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay
Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.
Taysha Q1 net loss $42.4M; FDA aligns on TSHA-102 BLA submission pathway
Net loss $42.4M ($0.12/sh) vs $21.5M ($0.08/sh) Q1 2025; R&D expense doubled to $33.8M on PPQ and clinical costs.
Taysha reports FY2025 net loss $109M; TSHA-102 pivotal trial dosing on track to complete Q2 2026
Net loss $109.0M ($0.34/share) vs $89.3M ($0.36) in 2024; R&D expenses rose to $86.4M.
Taysha Gene Therapies: TSHA-102 gets FDA Breakthrough Therapy, Q3 net loss $32.7M
FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome; FDA alignment finalized on REVEAL pivotal trial protocol with 6-month interim analysis to expedite BLA.
Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires
Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.
All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.
FDA Breakthrough Therapy designation for TSHA-102 based on Part A data from 12 patients showing 100% response rate on milestone gain.
Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025
Cash $312.8M after $230M follow-on offering; runway extended into 2028.
Taysha Gene Therapies shareholders approve authorized share increase to 700M
Authorized common stock increased from 400M to 700M shares; approved 171.3M for, 8.2M against.
Taysha reports FDA-aligned pivotal trial for TSHA-102; 100% of Part A patients gained milestones
FDA aligned on single-arm pivotal Part B trial (N=15) for TSHA-102 in Rett syndrome patients ≥6 years; primary endpoint: developmental milestone gain/regain.
Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.
100% of 10 patients in Part A gained/regained ≥1 developmental milestone post-TSHA-102, with ~0% likelihood from natural history data.
Taysha secures FDA alignment on TSHA-102 pivotal trial design; Q1 net loss $21.5M
FDA alignment on pivotal Part B trial design; IND amendment with protocol/SAP expected Q2 2025, potentially expediting registration.
Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.
Taysha Q3 net loss $25.5M; TSHA-102 high dose safe; FDA aligns on pivotal trial design
Net loss $25.5M ($0.10/sh) vs $117.1M loss in Q3 2023; cash $157.7M into Q4 2026.
Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025
Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.
Taysha launches $75M public offering; reports positive clinical data in Rett syndrome
Commenced underwritten public offering of up to $75M in common stock and pre-funded warrants; underwriters have 30-day option for additional 15%.
Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants
Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.
Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.
Taysha Gene Therapies holds 2024 annual meeting; directors elected and auditor ratified
Shareholders elect Sean Stalfort and Alison Long as directors until 2027.
Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation
Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.
Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients
Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.
First pediatric patient dosed with TSHA-102 in REVEAL Phase 1/2 trial for Rett syndrome
First pediatric patient (female, 5-8 years, stage 3 Rett syndrome) dosed at RUSH University Medical Center.
Taysha grants ~5.3M options and RSUs to top executives; adopts 4M-share inducement plan
CEO Sean Nolan receives 1,184,688 options and 1,184,688 RSUs (total ~2.37M shares).
Taysha Gene Therapies stockholders approve doubling authorized common stock to 400M shares
Special meeting on Nov 15, 2023: 72.16% of shares represented; amendment passed with 133,386,292 votes for.
Taysha Q3 net loss $117.1M on warrant expense; TSHA-102 well-tolerated with clinical improvements
Net loss $117.1M ($0.93/shr) includes $100.5M non-cash fair value change in warrant liability; prior year net loss $26.5M.
Taysha Gene Therapies appoints Alison Long to Board; Kathleen Reape resigns
Kathleen Reape resigns from Board effective Nov 1, 2023, per employer governance rules; no disagreement with company.
Taysha doses second Rett syndrome patient with TSHA-102 in REVEAL Phase 1/2 adult trial
Second adult patient dosed with TSHA-102 in REVEAL Phase 1/2 adult trial for Rett syndrome in Canada.
Taysha discontinues TSHA-120 in GAN; extends cash runway to Q4 2025 for TSHA-102
Taysha discontinues TSHA-120 for giant axonal neuropathy after FDA Type C feedback cited study design challenges for BLA.
Taysha Gene Therapies regains compliance with Nasdaq listing rules
Received Nasdaq notice on Aug 28, 2023, confirming compliance with minimum Market Value of Listed Securities of $50M.
Taysha Gene Therapies receives FDA Fast Track Designation for TSHA-102 in Rett syndrome
FDA granted Fast Track Designation for TSHA-102, an AAV9 gene therapy for Rett syndrome.
Taysha raises $150M PIPE; first Rett patient data shows clinical improvement
Gross proceeds of $150M from PIPE: 122.4M shares at $0.90/share and 44.3M pre-funded warrants.
Taysha Gene Therapies receives Nasdaq notice for non-compliance with MVLS minimum $50M
Received written notice from Nasdaq on Aug 3, 2023 for failing to meet $50M minimum MVLS requirement.
Taysha Gene Therapies gets IDMC nod to continue REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome
IDMC recommended trial continuation after review of initial clinical data from first adult dosed with TSHA-102.
Taysha reports new TSHA-120 data analysis supports FDA path; TSHA-102 first patient dosed
New TSHA-120 analysis shows 99% probability of slowing disease progression on mFARS and MFM32 Domain 3; FDA meeting expected Q3 2023.
Taysha stockholders approve reverse stock split and authorized share reduction
Reverse stock split authorized with ratio range of 1:5 to 1:20; 43.1M for, 10.5M against.
Taysha regains Nasdaq independence compliance; Manning resigns, Stalfort appointed
Paul Manning resigned from board effective June 20, 2023 to enable compliance with Nasdaq Rule 5605(b)(1); remains as non-voting observer.
Taysha grants performance-based options to CEO (666.5K), President (477.2K), CFO (268K)
CEO Sean Nolan receives 666,500 options; President Sukumar Nagendran 477,150; CFO Kamran Alam 267,975.
Taysha doses first patient with TSHA-102 in Phase 1/2 REVEAL trial for Rett syndrome
First adult patient received TSHA-102, an AAV9 gene therapy using miRARE technology to regulate MECP2.
Taysha TSHA-102 data: safe in wild-type mice, extends survival >4x in Rett model
New wild-type mouse data: TSHA-102 showed no toxicity or survival reduction over 36 weeks, no impact on neurobehavioral function.
Taysha completes screening for Rett syndrome gene therapy trial; reports Q1 net loss of $17.6M
Screening completed for first adult patient in Phase 1/2 REVEAL trial of TSHA-102 for Rett syndrome; dosing expected Q2 2023.
Taysha Gene Therapies receives Nasdaq bid price deficiency notice; board changes announced
Received Nasdaq notice on April 25, 2023 for minimum bid price below $1.00 for 30 consecutive days.
Taysha reports Q4 net loss $55.7M; cash $87.9M; progress on Rett and GAN trials
Net loss Q4 2022: $55.7M ($0.99/shr) vs $50.4M Q4 2021; full year loss $166.0M vs $174.5M.
Taysha Gene Therapies finalizes separation with ex-CEO, includes RSU award and board resignation
Ex-CEO R.A. Session II resigned from operating role on Dec 16, 2022; severance agreement finalized March 7, 2023.
Taysha receives FDA feedback on TSHA-120 GAN; sets Rett syndrome milestones for 2023
FDA acknowledged MFM32 as acceptable endpoint; recommended double-blind placebo-controlled design for TSHA-120 BLA.
Taysha Gene Therapies CMO Suyash Prasad departs effective immediately
Chief Medical Officer Suyash Prasad separated from Taysha on Jan 12, 2023 by mutual agreement.
Taysha Gene Therapies: CEO salary $600K, President $565K; equity grants of 1.1M and 790K options
Sean Nolan appointed CEO effective Dec 16, 2022; base salary $600K, annual target bonus 60% of base.
On October 30, 2023, the Board appointed Alison Long to serve as a director of the Company, effective immediately following Dr. Reape’s resignation (the “ Effective Time ”).
Kathleen Reape provided notice to the board of directors (the “ Board ”) of Taysha Gene Therapies, Inc. (the “C ompany ”) of her decision to resign from the Board and all committees thereof, effective November 1, 2023, in accordance with the governance guidelines of Dr. Reape’s employer and not as a result of any disagreement with the Company.
on June 21, 2023, the Board appointed Sean Stalfort to serve as a director of the Company, effective immediately following Mr. Manning’s resignation
on June 20, 2023, Paul B. Manning provided notice to the Board of his decision to resign from the Board and all committees thereof
Effective immediately prior to the conclusion of the 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”), the Company expects that Dr. Reape will resign as a Class III director of the Company. Upon her resignation, the Board intends to appoint Dr. Reape as a Class I director of the Company to serve until the 2024 annual meeting of stockholders.
Kathleen Reape provided notice to the board of directors (the “ Board ”) of the Company of her decision to resign from the Board, effective November 1, 2023.
On December 16, 2022 (the “ Separation Date ”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately.
On March 2, 2023, Mr. Session notified the Board of his resignation from the Board and all committees thereof effective immediately.
On January 12, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) and Suyash Prasad, the Company’s Chief Medical Officer, mutually agreed to Dr. Prasad’s separation from the Company, effective immediately.
the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective December 16, 2022.
the Company’s board of directors (the “ Board ”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022.
Dr. Suyash Prasad’s title was changed from Chief Medical Officer and Head of Research and Development to Chief Medical Officer, effective as of Dr. Nagendran’s appointment.
Max materiality 0.90 · Median 0.70 · Most common event other_material